<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159393">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023789</url>
  </required_header>
  <id_info>
    <org_study_id>09-386</org_study_id>
    <secondary_id>ACTRN12610000131055</secondary_id>
    <secondary_id>REFCTRI000460, 03-05-2010</secondary_id>
    <nct_id>NCT01023789</nct_id>
  </id_info>
  <brief_title>ABSORB EXTEND Clinical Investigation</brief_title>
  <acronym>ABSORB EXTEND</acronym>
  <official_title>ABSORB EXTEND Clinical Investigation: A Continuation in the Clinical Evaluation of the ABSORB Bioresorbable Vascular Scaffold (BVS) System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ABSORB EXTEND trial is to continue the assessment of the safety and performance of the
      ABSORB Bioresorbable Vascular Scaffold (BVS) System

      ABSORB BVS is currently in development at Abbott Vascular.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(This trial has no primary outcome, all outcomes are of equal weight) Acute success (clinical device and clinical procedure)</measure>
    <time_frame>Acute</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death (CD)</measure>
    <time_frame>30, 180 days, and 1, 2, and 3 years.</time_frame>
    <description>Subjects in the MSCT subgroup will also have clinical follow-up at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI)</measure>
    <time_frame>30, 180 days, and 1, 2, and 3 years</time_frame>
    <description>Subjects in the MSCT subgroup will also have clinical follow-up at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>30, 180 days, and 1, 2, and 3 years</time_frame>
    <description>Subjects in the MSCT subgroup will also have clinical follow-up at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven MACE (ID MACE)</measure>
    <time_frame>30, 180 days, and 1, 2, and 3 years</time_frame>
    <description>Subjects in the MSCT subgroup will also have clinical follow-up at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia driven Target Vessel Failure (ID TVF)</measure>
    <time_frame>30, 180 days, and 1, 2, and 3 years</time_frame>
    <description>Subjects in the MSCT subgroup will also have clinical follow-up at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (ID TLR)</measure>
    <time_frame>30, 180 days and 1, 2, and 3 years</time_frame>
    <description>Subjects in the MSCT subgroup will also have clinical follow-up at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (ID TVR)</measure>
    <time_frame>30, 180 days and 1, 2, and 3 years</time_frame>
    <description>Subjects in the MSCT subgroup will also have clinical follow-up at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scaffold thrombosis</measure>
    <time_frame>30, 180 days, and 1, 2, and 3 years</time_frame>
    <description>Subjects in the MSCT subgroup will also have clinical follow-up at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT: Descriptive analysis of strut, lesion and vessel morphology post-procedure</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT: Scaffold area post-procedure (if analyzable)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT: Lumen area</measure>
    <time_frame>post-procedure and at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT: Minimum luminal area (MLA)</measure>
    <time_frame>post-procedure and at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT: Incomplete apposition (baseline), persisting incomplete apposition, late incomplete apposition</measure>
    <time_frame>2 years (if analyzable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic OCT subgroup: Treated site Late Loss (LL)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic OCT subgroup: Treated segment LL</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic OCT subgroup: Proximal LL (proximal defined as within 5 mm of tissue proximal to scaffold placement)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic OCT subgroup: Distal LL (distal defined as within 5 mm of tissue distal to scaffold placement)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic OCT subgroup: Treated site and treated segment Minimum Luminal Diameter (MLD)</measure>
    <time_frame>post-procedure and at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic OCT subgroup: Treated site and treated segment % Diameter Stenosis (DS)</measure>
    <time_frame>post-procedure and at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic OCT subgroup: Treated site and treated segment Angiographic Binary Restenosis (ABR) rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic OCT subgroup: Aneurysm, thrombus, persisting dissection</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS OCT subgroup: Vessel area</measure>
    <time_frame>post-procedure and at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS OCT subgroup: Scaffold area (if analyzable)</measure>
    <time_frame>post-procedure and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS OCT subgroup: Minimum luminal area (MLA)</measure>
    <time_frame>post-procedure and at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS OCT subgroup: Treated site %Volume Obstruction (VO)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSCT subgroup: Descriptive analysis of vascular and scaffold morphology</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS OCT subgroup: Incomplete apposition (baseline), persisting incomplete apposition, late incomplete apposition</measure>
    <time_frame>2 years (if analyzable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia driven Non-Target Vessel Revascularization (ID non- TVR)</measure>
    <time_frame>30, 180 days and 1, 2, and 3 years</time_frame>
    <description>Subjects in the MSCT subgroup will also have clinical follow-up at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumen area</measure>
    <time_frame>post-procedure and at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia driven Non-Target Vessel Revascularization (ID non-TVR)</measure>
    <time_frame>30, 180 days and 1, 2, and 3 years</time_frame>
    <description>Subjects in the MSCT subgroup will also have clinical follow-up at 18 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">807</enrollment>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>ABSORB BVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABSORB Bioresorbable Vascular Scaffold (BVS) System implantation in the treatment of coronary artery disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ABSORB BVS</intervention_name>
    <description>ABSORB Bioresorbable Vascular Scaffold (BVS) System implantation</description>
    <arm_group_label>ABSORB BVS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Up to two de novo lesions can be treated, each located in a separate native
             epicardial vessel.

          -  Target lesion(s) must be located in a native coronary artery where target vessel(s)
             diameter is ≥ 2.0 mm and ≤ 3.3 mm and target lesion length is ≤ 28 mm, both assessed
             by on-line QCA.

          -  Target lesion(s) must be in a major artery or branch with a visually estimated
             stenosis of ≥ 50% and &lt; 100% with a TIMI flow of ≥ 1.

          -  If two treatable lesions meet the inclusion criteria they must be in separate major
             epicardial vessels (LAD with septal and diagonal branches, LCX with obtuse marginal
             and/or ramus intermedius branches and RCA and any of its branches).

          -  Percutaneous interventions for lesions in a non-target vessel are allowed if done ≥
             30 days prior to or if planned to be done 6 months after the index procedure.

          -  Percutaneous intervention for lesions in the target vessel are allowed if done &gt; 6
             months prior to or if planned to be done 6 months after the index procedure.

        Exclusion Criteria:

          -  Lesion(s) located within an arterial or saphenous vein graft or distal to a diseased
             (defined as vessel irregularity per angiogram and &gt; 20% stenosed lesion by visual
             estimation) arterial or saphenous vein graft.

          -  Lesion(s) involving a bifurcation with side branch vessel ≥ 2 mm in diameter and/or
             ostial lesion &gt; 40% stenosed by visual estimation or side branch requiring
             predilatation.

          -  Total occlusion (TIMI flow 0), prior to wire passing.

          -  Target vessel(s) contains visible thrombus.

          -  Another clinically significant lesion is located in the same epicardial vessel
             (including side branch) as the target lesion(s).

          -  Subject has received brachytherapy in any epicardial vessel (including side
             branches).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Abizaid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Cardiologia Dante Pazzanese Unidadae II Recepcao de Angioplastia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Serruys, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Thoraxcenter-Erasmus University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Cardiovascular de Buenos Aires-ICBA</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1428</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Heart Clinic, The Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Hospital</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Center</name>
      <address>
        <city>Victoria</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Linz</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze-Lieve VrouweZiekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia Dante Pazzanese Unidadae II Recepcao de Angioplastia</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04012-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente Isreaelita Brasileira Hospital Albert Einstein</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05652-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Coração Triângulo Mineiro</name>
      <address>
        <city>Uberlandia</city>
        <zip>38400-368</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Århus University Hospital</name>
      <address>
        <city>Århus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jacques Cartier (ICPS)</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital De Rangueil - CHU</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Berlin Campus Steglitz</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni.Klinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>Hyderabaad</city>
        <state>Andhar Pradesh</state>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE Hospital</name>
      <address>
        <city>Hyderabaad</city>
        <state>Andhra Pradesh</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAL Hospital And Medical Institute</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Institute of Medical Sciences</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madras Medical Mission</name>
      <address>
        <city>Chennai</city>
        <zip>600 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medanta -The Medicity</name>
      <address>
        <city>Gurgaon</city>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjay Gandhi Postgraduate Institute of Medical Sciences</name>
      <address>
        <city>Lucknow</city>
        <zip>226014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Escorts Heart Institute &amp; Research Centre</name>
      <address>
        <city>New Delhi</city>
        <zip>110 070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catanzaro University Hospital</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University</name>
      <address>
        <city>Tokyo</city>
        <state>Itabashi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohama City Eastern Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Sakyo-ku</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mitsui Memorial Hospital</name>
      <address>
        <city>Chiyoda-ku</city>
        <zip>101-8643</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Jantung Negara</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina ZH Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Angiography Unit</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Krakow</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunninghill Hospital</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital do Meixoeiro</name>
      <address>
        <city>Vigo Pontevedra</city>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern, Kardiologie</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Niao-Sung Hsiang</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 20, 2016</lastchanged_date>
  <firstreceived_date>November 30, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting stent</keyword>
  <keyword>Stents</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Bioabsorbable</keyword>
  <keyword>Bioresorbable</keyword>
  <keyword>Scaffold</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
